Funding for this research was provided by:
Centers for Disease Control and Prevention (AMD-133)
Received: 9 February 2018
Accepted: 29 August 2018
First Online: 17 September 2018
Ethics approval and consent to participate
: Ethics approval for the use of anonymized, de-identified, non-reidentifiable blood samples as non-engaged research was granted by Centers for Disease Control and Prevention Division of Parasitic Diseases and Malaria Human Subjects Review, approval number 2016-314. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention/the Agency for Toxic Substances and Disease Registry.
: E.T., R.S.B., C.O., and B.R.F. have submitted a patent (E-113-2017/0; I-024-16) for the use of restriction enzymes to reduce host DNA in TADS analyses. The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.